Drug intelligence / Profile preview

SPARC0913

Development stage: Phase 3
Lead developer: SPARC
Modality: Small Molecules
Administration: Ophthalmic

Overview

SPARC0913 is a small molecule drug developed by Sun Pharma Advanced Research Company (SPARC) for the treatment of eye diseases, specifically primary open-angle glaucoma and ocular hypertension. The drug has undergone clinical evaluation to assess its long-term safety in patients with these conditions. While detailed mechanistic information is not publicly available, it was studied in a multicenter, open-label Phase 3 trial involving subjects with primary open-angle glaucoma or ocular hypertension who received the medication for 24 weeks[1][2][3]. The highest reported development phase is Phase 3.

Brand names: SPARC0913SPARC-0913SPARC 0913
Other names: SPARC0913SPARC-0913SPARC 0913

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on SPARC0913.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPARC0913.

Explore the full profile